Clinical trial
A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults
NCT02661490 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 1, 2016
- Completion date
- September 29, 2017
- Enrollment
- 320 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
norovirus